Poster Abstract Session:
72. Pneumococcal Vaccines
Friday, October 21, 2011: 12:15 PM-2:15 PM
Room: Poster Hall B1

Topical Category: I. Adult and Pediatric Vaccines

Tracks: Adult ID, Pediatric ID

Presentations:

656
Invasive Pneumococcal Disease in Alaska:á Impact of the 13-valent Pneumococcal Conjugate Vaccine
Michael Bruce, MD, MPH ; Jay Wenger, MD ; Tammy Zulz, MPH ; Rosalyn Singleton, MD ; Lisa Bulkow, MS ; Karen Rudolph, PhD ; Debby Hurlburt, RN BSN ; Thomas Hennessy, MD MPH

657
Public Health & Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Adult Vaccination in the Context of a Flu Pandemic in the US
Lisa McGarry, MPH ; Gregory Hill, BA ; Kristen Gilmore, BA ; Reiko Sato, Ph.D. ; David Strutton, Ph.D. ; Jaime Rubin, MA ; Milton Weinstein, PhD

661
Long-Term Immune Responses to Pneumococcal Conjugate Vaccines in Children Previously Vaccinated with 7-valent Pneumococcal Conjugate Vaccine
Nicola Klein, MD, PhD ; Kathleen Ensor, BA, RN ; Sylvie Jouve, PhD ; Michele Moscariello ; Paul McGovern

662
Invasive pneumococcal disease in Massachusetts children following introduction of PCV13
Inci Yildirim, MD MSc ; Katherine Hsu, MD, MPH ; Abbie Stevenson, BS ; Stephen I. Pelton, MD MPH

663
Impact of Infant Pneumococcal Vaccination on The Epidemiology of Invasive Pneumococcal Disease in Belgium, 2002-2010
Laurens Liesenborghs ; Jan Verhaegen, MD, PhD ; Willy E Peetermans, MD, PhD ; Johan Flamaing, MD, PhD

664
A Phase 3, Open-label, Follow-up Trial Evaluating the Safety and Immunogenicity of a Subsequent Dose of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Elderly Adults who Received PCV13 Followed by 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in a Prior Trial
Christine Juergens, MD ; Pierre de Villiers, PhD ; Keymanthri Moodley, MBChB, DPhil ; Deepthi Jayawardene, MS ; Kathrin U. Jansen, PhD ; Daniel A Scott, MD ; Emilio A. Emini, MD ; William Gruber, MD ; Beate Schmoele-Thoma, MD

665
A Phase 3, Randomized, Active-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of áSequential Administration of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Administered at 1-year Intervals in PPSV23- na´ve Adults 60-64 Years of Age
Richard N Greenberg, MD ; Alejandra Gurtman, MD ; Robert Frenck, MD ; Cynthia B. Strout, MD ; Kathrin U. Jansen, PhD ; Deepthi Jayawardene, MS ; Daniel A Scott, MD ; Emilio A. Emini, MD ; William Gruber, MD ; Beate Schmoele-Thoma, MD

666
Early Evidence of 13 Valent Pneumococcal Conjugate Vaccine Impact on Carriage of Vaccine Serotypes
Katherine Hsu, MD, MPH ; Anita Loughlin, PhD ; Abbie Stevenson, BS ; Stephen I. Pelton, MD MPH

667
Streptococcus pneumoniae serotypes in Utah adults with invasive pneumococcal disease at the end of the PCV7 era
Brian Kendall, MD ; Kristin Dascomb, MD, PhD ; Rajesh Mehta, RPh, MS ; Edward Mason, PhD ; Krow Ampofo, MD ; David Pombo, MD ; Andrew Pavia, MD, FIDSA ; Carrie L. Byington, MD

668
Eradication of 7-valent Pneumococcal Conjugate Vaccine (PCV7) Serotypes Causing Invasive Pneumococcal Disease (IPD) in Young Children in Calgary, Canada
Jenine Leal, MSc ; Otto Vanderkooi, MD ; Deirdre Church, MD PhD ; Judy MacDonald, MD ; David Scheifele, MD ; James D. Kellner, MD

CME Credits:

ACPE Credits:

ACPE Number:


Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.